Metropolitan Life Insurance CO Cyclerion Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.8 - $13.43 $16,416 - $122,481	-9,120 Closed	0 $0
Q3 2019 Jul 12, 2023	BUY	$8.12 - $14.54 $74,054 - $132,604	9,120 New	9,120 $110,000
Q3 2019 Mar 30, 2023	BUY	$8.12 - $14.54 $37,709 - $67,523	4,644 Added 103.75%	9,120 $110,000
Q3 2019 Nov 14, 2019	BUY	$8.12 - $14.54 $37,709 - $67,523	4,644 Added 103.75%	9,120 $111,000
Q2 2019 Jul 12, 2023	BUY	$9.6 - $22.85 $52,089 - $123,984	5,426 New	5,426 $62,000
Q2 2019 Mar 30, 2023	BUY	$9.6 - $22.85 $42,969 - $102,276	4,476 New	4,476 $51,000
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $42,969 - $102,276	4,476 New	4,476 $51,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.